Pharmacyclics Stock Price, News & Analysis (NASDAQ:PCYC)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Pharmacyclics (NASDAQ:PCYC)

Pharmacyclics logoPharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.

Receive PCYC News and Ratings via Email

Sign-up to receive the latest news and ratings for PCYC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:PCYC
CUSIP71693310
WebN/A
Phone+1-408-7740330

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS$0.92
Net IncomeN/A
Net Margins2.02%
Return on Equity1.93%
Return on Assets1.52%

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

Pharmacyclics (NASDAQ:PCYC) Frequently Asked Questions

What is Pharmacyclics' stock symbol?

Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC."

How were Pharmacyclics' earnings last quarter?

Pharmacyclics, Inc. (NASDAQ:PCYC) announced its earnings results on Friday, May, 1st. The biopharmaceutical company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. The biopharmaceutical company had revenue of $206 million for the quarter, compared to the consensus estimate of $226.27 million. Pharmacyclics had a return on equity of 1.93% and a net margin of 2.02%. View Pharmacyclics' Earnings History.

Who are some of Pharmacyclics' key competitors?

How do I buy Pharmacyclics stock?

Shares of Pharmacyclics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Pharmacyclics?

Pharmacyclics' mailing address is 995 E ARQUES AVE, SUNNYVALE, CA 94085-4521, United States. The biopharmaceutical company can be reached via phone at +1-408-7740330.


MarketBeat Community Rating for Pharmacyclics (PCYC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  295 (Vote Outperform)
Underperform Votes:  240 (Vote Underperform)
Total Votes:  535
MarketBeat's community ratings are surveys of what our community members think about Pharmacyclics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pharmacyclics (NASDAQ:PCYC) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Pharmacyclics (NASDAQ:PCYC) Earnings History and Estimates Chart

Earnings by Quarter for Pharmacyclics (NASDAQ:PCYC)

Pharmacyclics (NASDAQ PCYC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2015Q115$0.11$0.13$226.27 million$206.00 millionViewN/AView Earnings Details
2/18/2015Q414$0.76$0.96$267.50 million$290.00 millionViewN/AView Earnings Details
11/4/2014Q314$0.37$0.69$201.50 million$207.10 millionViewN/AView Earnings Details
7/31/2014Q214($0.23)($0.26)$95.88 million$113.00 millionViewN/AView Earnings Details
5/2/2014Q114$0.17$0.40$105.38 million$119.40 millionViewN/AView Earnings Details
2/20/2014Q413$0.67$0.95$85.69 million$123.60 millionViewN/AView Earnings Details
11/7/2013Q3 2013$0.31$0.55ViewN/AView Earnings Details
7/31/2013Q2 2013($0.07)$0.26$52.00 million$54.70 millionViewN/AView Earnings Details
5/1/2013Q3 2013($0.03)($0.40)$2.84 millionViewN/AView Earnings Details
2/14/2013Q2 2013$0.29$0.62$45.74 million$57.96 millionViewN/AView Earnings Details
11/5/2012Q113$0.75$1.14$87.64 million$102.70 millionViewN/AView Earnings Details
9/5/2012Q412($0.27)($0.22)$3.49 million$2.10 millionViewN/AView Earnings Details
5/10/2012($0.20)($0.14)ViewN/AView Earnings Details
2/9/2012($0.18)$0.82ViewN/AView Earnings Details
11/7/2011Q3 2011($0.15)($0.21)ViewN/AView Earnings Details
9/12/2011Q2 2011($0.14)($0.18)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.13)($0.15)ViewN/AView Earnings Details
2/4/2011Q4 2010($0.12)($0.14)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.13)($0.13)ViewN/AView Earnings Details
9/13/2010Q2 2010($0.07)($0.13)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.08)($0.06)ViewN/AView Earnings Details
2/11/2010Q4 2009($0.10)($0.06)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.12)($0.12)ViewN/AView Earnings Details
9/17/2009Q2 2009($0.18)($0.20)ViewN/AView Earnings Details
4/23/2009Q1 2009($0.19)($0.25)ViewN/AView Earnings Details
2/13/2009Q4 2008($0.17)($0.19)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.25)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.26)($0.18)ViewN/AView Earnings Details
4/24/2008Q1 2008($0.29)($0.27)ViewN/AView Earnings Details
1/24/2008Q4 2007($0.28)($0.23)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Pharmacyclics (NASDAQ:PCYC) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Pharmacyclics (NASDAQ:PCYC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Pharmacyclics (NASDAQ PCYC) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Pharmacyclics (NASDAQ:PCYC)

Pharmacyclics (NASDAQ PCYC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2015Manmeet Singh SoniCFOSell27,514$254.24$6,995,159.36View SEC Filing  
3/12/2015Heow TanInsiderSell1,000$254.51$254,510.00View SEC Filing  
11/12/2014Maky ZanganehCOOSell30,482$134.69$4,105,620.58View SEC Filing  
11/10/2014Maky ZanganehCOOSell23,000$133.83$3,078,090.00View SEC Filing  
11/10/2014Richard B LoveGeneral CounselSell1,500$133.87$200,805.00View SEC Filing  
11/7/2014Maky ZanganehCOOSell1,551$135.01$209,400.51View SEC Filing  
11/7/2014Maria FardisInsiderSell5,000$134.50$672,500.00View SEC Filing  
9/4/2014Maky ZanganehCOOSell12,000$121.75$1,461,000.00View SEC Filing  
8/27/2014Richard B LoveGeneral CounselSell1,500$124.00$186,000.00View SEC Filing  
8/13/2014Heow TanInsiderSell10,000$123.58$1,235,800.00View SEC Filing  
8/7/2014Jesse McgreivyInsiderSell34,062$120.92$4,118,777.04View SEC Filing  
3/5/2014Boultbee Paula SjovallEVPSell20,000$138.22$2,764,400.001,739View SEC Filing  
3/5/2014Gregory HemmiVPSell15,000$140.00$2,100,000.0038,004View SEC Filing  
3/5/2014Jesse McgreivyInsiderSell6,563$139.66$916,588.58View SEC Filing  
3/4/2014Betty ChangVPSell17,500$137.97$2,414,475.003,754View SEC Filing  
2/27/2014Den Broek Richard VanDirectorSell78,835$146.63$11,559,576.05View SEC Filing  
12/19/2013Heow TanInsiderSell5,000$100.87$504,350.00169View SEC Filing  
12/18/2013Gregory HemmiVPSell20,000$100.52$2,010,400.0025,004View SEC Filing  
12/16/2013Rainer ErdtmannVPSell54,000$107.77$5,819,580.005,497View SEC Filing  
6/6/2013Scott T ShearerVPSell18,750$85.17$1,596,937.50View SEC Filing  
5/31/2013Heow TanInsiderSell5,237$91.84$480,966.08View SEC Filing  
5/31/2013Jesse McgreivyVPSell14,479$91.13$1,319,471.27View SEC Filing  
2/5/2013David J LouryInsiderSell20,000$70.58$1,411,600.00View SEC Filing  
12/28/2012Den Broek Richard VanDirectorSell30,285$57.99$1,756,227.15View SEC Filing  
12/27/2012Gregory HemmiVPSell13,000$59.20$769,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pharmacyclics (NASDAQ PCYC) News Headlines

Source:
DateHeadline
Calithera Biosciences Announces Appointment Of Sumita Ray As General CounselCalithera Biosciences Announces Appointment Of Sumita Ray As General Counsel
www.thestreet.com - October 3 at 10:29 AM
Comparing Pharmacyclics (PCYC) and Bio-Techne Corp (TECH)Comparing Pharmacyclics (PCYC) and Bio-Techne Corp (TECH)
www.americanbankingnews.com - September 28 at 4:22 PM
Can a 72-year-old, surf-loving Scientologist score again with this med device startup?Can a 72-year-old, surf-loving Scientologist score again with this med device startup?
www.bizjournals.com - April 7 at 11:50 AM
UPDATE 1-TG Therapeutics leukemia drug clears hurdle in key studyUPDATE 1-TG Therapeutics' leukemia drug clears hurdle in key study
www.businessinsider.com - March 7 at 9:50 AM
These drug and medical device companies made the most payments to Chicago hospitalsThese drug and medical device companies made the most payments to Chicago hospitals
www.bizjournals.com - March 2 at 8:44 AM
Here’s where a Pinellas billionaire and top donor to Church of Scientology is putting his investment dollarsHere’s where a Pinellas billionaire and top donor to Church of Scientology is putting his investment dollars
www.bizjournals.com - March 2 at 8:44 AM
Former Pharmacyclics execs take 17% stake in Pulse Bio; shares up 33%Former Pharmacyclics execs take 17% stake in Pulse Bio; shares up 33%
seekingalpha.com - February 10 at 9:47 AM
Abbvie (ABBV) Imbruvica Approved in Lymphoma IndicationAbbvie (ABBV) Imbruvica Approved in Lymphoma Indication
www.zacks.com - January 20 at 7:59 PM
AbbVie (ABBV) Announces FDA Approval for IMBRUVICA to Treat Specifically Indicated for R/R MZL - StreetInsider.comAbbVie (ABBV) Announces FDA Approval for IMBRUVICA to Treat Specifically Indicated for R/R MZL - StreetInsider.com
www.streetinsider.com - January 19 at 11:50 PM
AbbVie (ABBV) Announces Presentation of Positive IMBRUVICA Phase 2 Data in cGVHDAbbVie (ABBV) Announces Presentation of Positive IMBRUVICA Phase 2 Data in cGVHD
www.streetinsider.com - December 7 at 7:04 PM
AbbVie (ABBV) Updates on Five-Year IMBRUVICA Data in CLL/SLL; Strong CR/PR Results Noted - StreetInsider.comAbbVie (ABBV) Updates on Five-Year IMBRUVICA Data in CLL/SLL; Strong CR/PR Results Noted - StreetInsider.com
www.streetinsider.com - December 6 at 6:52 PM
AbbVie (ABBV) Announces Presentation of Positive IMBRUVICA Phase 2 Data in cGVHD - StreetInsider.comAbbVie (ABBV) Announces Presentation of Positive IMBRUVICA Phase 2 Data in cGVHD - StreetInsider.com
www.streetinsider.com - December 6 at 6:52 PM
IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and - PR Newswire (press release)IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and - PR Newswire (press release)
www.prnewswire.com - December 5 at 9:48 AM
Data at ASH 2016 Show Strong, Lasting Efficacy of Imbruvica®   (ibrutinib) Through Five Years of Treatment for ... - Business Wire (press release)Data at ASH 2016 Show Strong, Lasting Efficacy of Imbruvica® (ibrutinib) Through Five Years of Treatment for ... - Business Wire (press release)
www.businesswire.com - December 5 at 9:48 AM
Janssen Announces Follow-up Data on IMBRUVICA Phase 1b/2 as ... - StreetInsider.comJanssen Announces Follow-up Data on IMBRUVICA Phase 1b/2 as ... - StreetInsider.com
www.streetinsider.com - December 5 at 9:48 AM
Gilead Sciences Closes Above Its Downward Channel, Are Future Gains To Follow? - Seeking AlphaGilead Sciences Closes Above Its Downward Channel, Are Future Gains To Follow? - Seeking Alpha
seekingalpha.com - November 15 at 10:29 AM
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for - PR Newswire (press release)AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for - PR Newswire (press release)
www.prnewswire.com - September 26 at 11:30 AM
Goldman Sachs Talks Pfizers Acquisition Deal Of Medivation - BenzingaGoldman Sachs Talks Pfizer's Acquisition Deal Of Medivation - Benzinga
www.benzinga.com - August 24 at 9:50 AM
ACADIA Pharmaceuticals Could Be Acquired - Seeking AlphaACADIA Pharmaceuticals Could Be Acquired - Seeking Alpha
seekingalpha.com - June 7 at 9:30 AM
AbbVie (ABBV) Announces Additional Data on IMBRUVICA Phase 3 in CLL/SLL - StreetInsider.comAbbVie (ABBV) Announces Additional Data on IMBRUVICA Phase 3 in CLL/SLL - StreetInsider.com
www.streetinsider.com - June 6 at 10:26 AM
AbbVie (ABBV) Receives EC Approval of IMBRUVICA as CLL Treatment - StreetInsider.comAbbVie (ABBV) Receives EC Approval of IMBRUVICA as CLL Treatment - StreetInsider.com
www.streetinsider.com - May 31 at 7:01 PM
European Commission Approves IMBRUVICA® (ibrutinib) for First-Line Treatment of Patients with Chronic Lymphocytic ... - PR Newswire (press release)European Commission Approves IMBRUVICA® (ibrutinib) for First-Line Treatment of Patients with Chronic Lymphocytic ... - PR Newswire (press release)
www.prnewswire.com - May 31 at 6:38 AM
Tax Savvy Execs Work For $1, Get Paid Millions As Capital GainTax Savvy Execs Work For $1, Get Paid Millions As Capital Gain
www.forbes.com - May 2 at 8:43 AM

SEC Filings

Pharmacyclics (NASDAQ:PCYC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pharmacyclics (NASDAQ:PCYC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pharmacyclics (NASDAQ PCYC) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.